The prediabetes market was valued at USD 181.86 Million in 2025 and is expected to grow at a CAGR of 6.40%, reaching USD 338.18 Million by 2035. The market is supported by increasing awareness, early diagnosis, and adoption of advanced screening technologies for prediabetes. Growing demand for lifestyle management solutions, digital health tools, and continuous glucose monitoring further enhances adoption. Rising prevalence linked to obesity and sedentary lifestyles, coupled with expanding healthcare infrastructure, is anticipated to boost market growth over the forecast period.
Base Year
Historical Period
Forecast Period
According to NHS England, the prevalence of prediabetes reached over 3.6 million in 2023, an 18% rise from 2022, fueling market growth, especially among individuals under 40, and increasing demand for early detection and intervention solutions.
In April 2024, Sanofi launched Soliqua® in India, a once-daily injectable for type 2 diabetes and obesity. Its simplified regimen and affordable pricing are expected to drive adoption, positively impacting the prediabetes market growth.
The market is expanding due to rising awareness of lifestyle-related risk factors, increasing adoption of preventive healthcare solutions, advancements in diagnostic technologies, and growing initiatives promoting early intervention and patient education.
Compound Annual Growth Rate
6.4%
Value in USD Million
2026-2035
*this image is indicative*
Prediabetes represents an intermediate stage where blood glucose levels are higher than normal but not yet at diabetic levels, highlighting a critical window for prevention and intervention. Growing lifestyle changes, sedentary habits, and rising obesity rates are driving its global prevalence. The prediabetes market reflects increasing awareness, early diagnostic initiatives, and preventive treatment approaches, supported by healthcare advancements and government programs. With expanding therapeutic options and proactive patient engagement, the market is poised to grow at a CAGR of 6.40% during the forecast period of 2026-2035, offering opportunities for stakeholders across diagnostics, pharmaceuticals, and digital health solutions.
Rising Awareness of Prediabetes to Drive the Market Growth
The increasing awareness of prediabetes among adults is a significant growth driver in the market. According to the Cleveland Clinic, approximately 84 million adults in the United States are estimated to be prediabetic. The condition affects more than one in three adults under 65 and half of adults over 65. Despite its prevalence, over 80% of individuals with prediabetes remain undiagnosed due to the absence of noticeable symptoms. This growing recognition of the condition is prompting early screening and intervention efforts, thereby contributing to sustained market expansion.
Some of the trends in the market include dietary interventions and innovations in dual-action therapies.
Emphasis on Adopting Innovative Dietary Interventions
The use of targeted dietary interventions to support blood glucose management is a significant trend shaping the market. In January 2025, the BETA study conducted by the Quadram Institute demonstrated that regular consumption of broccoli soup could help normalize blood sugar levels in individuals with prediabetes. This 36-week double-blind trial also highlighted improvements in participants’ dietary habits and heightened awareness of nutrition. Such evidence-based dietary strategies are anticipated to enhance treatment approaches and contribute to sustained growth in the market.
Advancements in Dual-Action Therapies Driving Prediabetes Market Demand
The market is witnessing a trend toward therapies that combine weight management with diabetes prevention, reflecting the growing need for comprehensive interventions. In August 2024, the SURMOUNT-1 Phase 3 study highlighted that tirzepatide significantly reduced the risk of progression to type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight, while also achieving an average 22.9% weight reduction at the 15 mg dose. Such dual-action treatments demonstrate enhanced clinical outcomes, positioning the prediabetes market for sustained growth and increased adoption of innovative therapies.
Adults to Lead the Market by Age Group
The market is segmented by age group into pediatrics, adults, and geriatrics, reflecting the diverse needs across different populations. Among these, the adult segment is expected to dominate, owing to the higher prevalence and greater awareness of prediabetes management within this group. According to the Centers for Disease Control and Prevention (CDC), more than 1 in 3 American adults has prediabetes, highlighting the critical demand for targeted interventions, monitoring tools, and preventive strategies focused on adults.
The market is divided into regions such as the United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to lead the market, driven by rising prediabetes prevalence, increased awareness, and adoption of advanced care strategies. In December 2024, the American Diabetes Association released the Standards of Care in Diabetes-2025, highlighting early diagnosis, lifestyle interventions, pharmacotherapy, and technology-based management for prediabetes and type 2 diabetes. These evidence-based guidelines are expected to reinforce the United States’ position as a key market leader.
The key features of the market report comprise clinical trials analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Eli Lilly and Company is a leading global pharmaceutical firm actively advancing therapies in metabolic and cardiovascular health. At the American Diabetes Association’s 85th Scientific Sessions, Lilly highlighted new data on tirzepatide (Zepbound and Mounjaro), which showed sustained weight reduction and improved outcomes in adults with obesity and prediabetes. The company’s continued clinical research underscores its commitment to addressing prediabetes and related cardiometabolic risks through innovative treatments.
Bayer AG, a leading global life sciences company, has been actively engaged in diabetes research through its product Acarbose (marketed as Precose/Glucobay). The company conducted a large-scale Phase 3 clinical study to evaluate Acarbose in preventing or delaying the progression of prediabetes to type 2 diabetes. By focusing on impaired glucose homeostasis, Bayer demonstrated its commitment to addressing early-stage diabetes management and reducing associated cardiovascular risks.
Boehringer Ingelheim, a global research-driven biopharmaceutical company, is actively engaged in advancing solutions for diabetes and prediabetes care. Through its Canadian arm, the company partnered with McGill University Health Centre and others to launch the DECIDE-CV program, which integrates artificial intelligence, wearable devices, and electronic health records to improve early detection of type 2 diabetes in high-risk individuals, supporting preventive care and reducing healthcare burdens.
AstraZeneca plc, a global biopharmaceutical leader, has advanced its presence in the diabetes care segment with the US Food and Drug Administration’s 2024 approval of Farxiga (dapagliflozin) for pediatric type 2 diabetes patients aged 10 and older. Backed by strong Phase III T2NOW trial results, Farxiga demonstrated significant glycemic control, reinforcing AstraZeneca’s commitment to addressing rising diabetes prevalence and unmet needs in cardiovascular, renal, and metabolic health.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Sanofi, Merck & Co., Inc., Glenmark Pharmaceuticals, GSK plc, Pfizer Inc., and Biocon Limited.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drugs
Market Breakup by Age Group
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Country
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drugs |
|
| Breakup by Age Group |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share